Concord Drugs Ltd (CONCORD) is currently trading at 71.73 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Concord Drugs Limited is a prominent pharmaceutical company in India, established in 1995, focusing on manufacturing various pharmaceutical formulations including injectables, tablets, and capsules. The company operates two government-licensed manufacturing facilities equipped with advanced technology to ensure high-quality pharmaceutical production standards. Concord Drugs has diversified its offerings by including innovative drug delivery technologies like MUPS and sustained release pellets, enhancing its product portfolio. With a focus on contract manufacturing, Concord Drugs provides comprehensive pharmaceutical development, optimizing manufacturing services for diverse drug products.

Over the past 52 weeks, Concord Drugs Ltd has traded between a low of ₹29.00 and a high of ₹92.52. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Concord Drugs Ltd has a market capitalization of approximately 71.63. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Concord Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 140.65 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 71.63 Cr, Concord Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Concord Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Concord Drugs Ltd is 140.65. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.